Thread by @Rivkatweets

Massachusetts ME/CFS & FM Assoc. (@MassMECFS) is thrilled to announce NIH has awarded a $2.5 million grant for #MECFS to the two-woman Univ of Mass. Medical School (@UMassMedical) research team of Liisa Selin, MD, PhD, and Anna Gil, PhD

Press release: massmecfs.org/30-news/758-ex…

@MassMECFS is pleased to have supported this research team, including notifying our newsletter recipients that these innovative researchers had received @PlzSolveCFS's Ramsey award & needed blood. People responded enthusiastically, allowing this research to move forward.

Additionally, the UMass Medical School researchers met with the @MassMECFS Research Club & shared their cutting-edge findings. A video excerpt of that meeting can be found here: vimeo.com/524080450

Selin & Gil's research is summarized on this poster massmecfs.org/images/pdf/MEC…

It's also exciting to @MassMECFS that this NIH money is coming to a Massachusetts institution (@UMassMedical). After all Massachusetts is a medical hub for the world, & it should also be that for #MECFS

For more details, read the MassME press release: massmecfs.org/images/pdf/Sel…

This grant builds on the research Selin and Gil did with a small seed grant from @PlzSolveCFS's Ramsay Program.

Thanks, Drs. Liisa Selin and Anna Gil, for all your hard work for our #MECFS community!

From the press release:

Nancy Klimas, MD, Director of Nova Southeastern University's Institute for Neuro-Immune Medicine, recently awarded a $4 million grant from the Centers for Disease Control (@CDCgov) to study ME/CFS and Long COVID, says: "It’s exciting to see..."

"...Lisa Selin’s work move to the next level. Her focus on immune exhaustion is right on target. Immune restoration as a treatment focus will be important to ME/CFS, and also to the post-COVID illness that is being called #LongCOVID or Post-Acute Sequelae of SARS CoV-2 Infection"

From the press release: "This NIH RO1 grant, titled “Altered T cell Responses in ME/CFS” allows the researchers to examine the role of aberrant T cell responses in the immunopathogenesis of #MECFS patients."

From the press release: "Selin and Gil's recent research findings could point to potential biomarkers, treatments and ways of tracking response to therapy for the disease, things that have been sorely missing."